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The high prevalence of sleep apnea syndrome (SAS) and its direct relationship with
an augmented risk of cardiovascular disease (CVD) have raised SAS as a primary
public health problem. For this reason, extensive research aiming to understand the
interaction between both conditions has been conducted. The advances in non-invasive
autonomic nervous system (ANS) monitoring through heart rate variability (HRV) analysis
have revealed an increased sympathetic dominance in subjects suffering from SAS when
compared with controls. Similarly, HRV analysis of subjects with CVD suggests altered
autonomic activity. In this work, we investigated the altered autonomic control in subjects
suffering from SAS and CVD simultaneously when compared with SAS patients, as well
as the possibility that ANS assessment may be useful for the early stage identification of
cardiovascular risk in subjects with SAS. The analysis was performed over 199 subjects
from two independent datasets during night-time, and the effects of the physiological
response following an apneic episode, sleep stages, and respiration on HRV were
taken into account. Results, as measured by HRV, suggest a decreased sympathetic
dominance in those subjects suffering from both conditions, as well as in subjects with
SAS that will develop CVDs, which was reflected in a significantly reduced sympathovagal
balance (p < 0.05). In this way, ANS monitoring could contribute to improve screening
and diagnosis, and eventually aid in the phenotyping of patients, as an altered response
might have direct implications on cardiovascular health.
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1. INTRODUCTION
Sleep apnea syndrome (SAS) is a complex sleep-related breathing disorder characterized by a
repetitive total (apnea) or partial (hypopnea) upper-airway collapse (obstructive sleep apnea, OSA),
an absence of respiratory drive (central sleep apnea, CSA), or a combination of both (mixed sleep
apnea). During an OSA episode, forced inspiration against an obstructed upper airway leads to
exaggerated negative intrathoracic pressure and is accompanied by immediate hypoxia, which
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triggers a complicated autonomic response (Somers et al.,
2008) and large fluctuations in blood pressure (Peppard et al.,
2000) and heart rate (Leung and Douglas Bradley, 2001;
Caples et al., 2007). The apneic episode is often stopped by
the arousal of the subject, thus resulting in a fragmented
sleep. Combination of all these effects has been closely related
with excessive daytime sleepiness, chronic hypertension, and
increased mortality (Somers et al., 2008). Moreover, SAS has
been related with a 5-fold increase in the risk for developing
cardiovascular diseases (CVD), which could rise to 11-fold
if not conveniently treated (Peker et al., 2002). In this way,
SAS represents a well-known cause of secondary systemic
and pulmonary hypertension, and a significant risk factor for
coronary artery disease, cardiac arrhythmias, and heart failure
(Yacoub et al., 2017; Tietjens et al., 2019). Analogously, some
CVD such as heart failure, atrial fibrillation, or stroke may exert
a negative effect in SAS, as a deficient blood conduction could
lead to a dysregulation of PaCO2 and hence trigger CSA episodes
(Kasai et al., 2012).
Notwithstanding the characteristic physiological response to
an apneic episode shared by most of the patients, only some
of them will develop CVD. Since altered heart rate variability
(HRV) has been independently related to both conditions,
HRV analysis has attracted widespread interest in the field of
SAS (almost 200 publications in PubMed search including the
key words heart rate variability and apnea, considering only
the last 5 years). In this context, HRV analysis has revealed
altered sympathovagal balance during sleep in subjects suffering
from moderate or severe SAS when compared with healthy
controls (Gula et al., 2003; Penzel et al., 2003). Also 24-h
monitoring suggests altered autonomic control in SAS patients
(Aydin et al., 2004), which reflects in an increased sympathetic
dominance. Moreover, many physiological (e.g., hypertension,
diabetes) and psychosomatic (e.g., stress, depression) conditions
that constitute risk factors for CVD development, have also
been related with altered HRV and sympathovagal balance
(Thayer et al., 2010). Hence, HRV analysis could shed some
light on the role of autonomic nervous system (ANS) in the
interaction between SAS and CVD. Whereas, polysomnographic
(PSG) recordings remain the gold standard for the diagnosis
of SAS, it would be interesting to dispose of a simple tool
for the early identification of patients at cardiovascular risk,
thus improving their screening and prioritizing their treatment.
If there was a relationship between ANS activity, SAS and
CVD, HRV could represent such a tool. Nevertheless, previous
works aiming to characterize ANS activity in SAS patients
using HRV analysis usually include the apneic episodes (Gula
et al., 2003; Penzel et al., 2003; Aydin et al., 2004), so that
the increased sympathetic dominance observed in SAS could be
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BMI, Body Mass Index; CSA, Central Sleep Apnea; CVD, Cardiovascular Disease;
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biased by the sympathetic activation taking place in response to
an apnea, and might not reflect the baseline state of the ANS in
these subjects.
For these reasons, the aim of the present manuscript is 2-fold:
first, to evaluate whether imbalanced autonomic activity could be
related with CVD in SAS. Second, to investigate whether HRV
analysis could be a useful tool for the early stage identification
and screening of SAS patients at cardiovascular risk.
2. MATERIALS AND METHODS
Two independent databases were employed in this study, namely
the UZ Leuven and the Sleep Heart Health Study datasets. The
former was employed for assessing differences in ANS activity
between patients suffering from SAS or SAS plus additional
cardiac comorbidities. The latter was used to see if altered ANS
control can be assessed in subjects with SAS who will be latter
diagnosed with a cardiovascular comorbidity. Both datasets are
described below.
2.1. UZ Leuven Dataset
It is composed of 100 subjects (78 male, 22 female) who were
referred to the sleep laboratory of the University Hospital Leuven
(UZ Leuven, Leuven, Belgium) because of suspicion of SAS.
PSGs were acquired, revised, and annotated by sleep specialists
according to the AASM 2012 scoring rules (Berry et al., 2012).
Sleep annotations included a classification of the recording
period in rapid eye movement (REM) sleep and three non-REM
stages (NREM1-NREM3), as well as the time occurrence and
duration of each apneic/hypopneic episode and arousal. Sleep
stage annotations were available for each 30-s epoch during the
whole recording. In this study no difference was made between
light and deep NREM sleep, so that the sleep stage classification
was reduced to REM and NREM sleep. Only subjects with
an apnea/hypopnea index (AHI) greater or equal than 15
were included. Bipolar ECG (lead II) and thoracic respiratory
effort (recorded through respiratory inductive plethysmography)
signals were acquired with a sampling frequency of 500 Hz.
The database consists of:
• 50 control patients without cardiac comorbidity (previous
myocardial infarction, objective coronary disease,
revascularization, or stroke) and without cardiovascular
risk factors (hypertension, hyperlipidemia, diabetes), and
• 50 patients with cardiac comorbidity or cardiovascular
risk factors.
Subjects in both groups were matched in age (47.8 ±
10.9 years), gender (78 males, 22 females), body mass index
(BMI, 30.0 ± 4.5 kg/m2), and smoking habits (24 habitual
smokers at the time of the recordings). The average AHI was
41.3 ± 22.0, and the average recording duration was 09:02:33
(hh:mm:ss). Demographics of each group are summarized in
Table 1, where also the different medications used by the cardiac
comorbidity group are indicated. Data acquisition was carried
out in accordance with the recommendations of the UZ KU
Leuven, CommissieMedische Ethiek. The protocol was approved
by the Commissie Medische Ethiek UZ KU Leuven (ML 7962).
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TABLE 1 | Anthropometric data of the UZ Leuven dataset.
Control Cardiac comorbidity Total
Number of patients 50 50 100
Age (years) 47.3 ± 10.5 48.2 ± 11.4 47.8 ± 10.9
Gender (male/female) 39 / 11 39 / 11 78 / 22
BMI (kg/m2) 29.9 ± 4.6 29.8 ± 4.4 30.0 ± 4.5
AHI 39.8 ± 23.3 42.7 ± 21.1 41.3 ± 22.0
Active smokers 12 12 24
Medication intake 0 33 33
• β-blockers 0 22 22
• Ca channels inhibitors 0 8 8
• ACE inhibitors 0 12 12
• Diuretics 0 4 4
• Antidepressants 0 1 1
In the cardiac comorbidity group, subjects under medication intake can be treated with
various distinct drugs simultaneously. BMI, Body Mass Index; AHI, Apnea Hypopnea
Index; ACE, Angiotesin Converting Enzyme.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki.
2.2. Sleep Heart Health Study Dataset
The Sleep Heart Health Study (SHHS) was conducted by the
National Heart Lung & Blood Institute in order to assess
the negative cardiovascular effects induced by sleep-disordered
breathing in general population (Quan et al., 1997). Acquisition
was performed in two different sessions: a baseline session and a
follow up session, performed 3–8 years after the baseline session.
Despite the database is very extensive, we only considered a
subset of individuals appropriate for the purpose of this study.
Specifically, we were interested in those subjects who did not
present any cardiac comorbidity or cardiovascular risk factor
(the same ones than in the UZ Leuven dataset) at the baseline
recording, but developed any of them afterwards. Conditions for
inclusion were: baseline and follow up recordings available, no
cardiac comorbidity or cardiovascular risk factors at baseline and
subjects younger than 65 years, so that both databases were as
similar as possible.
Thirty-three subjects satisfied the above mentioned criteria
and suffered from a cardiac event at any point after the baseline
session, so they were labeled as cardiovascular event group.
Cardiac events considered for inclusion in this group were any
of the following: myocardial infarction, stroke, revascularization,
congestive heart failure, coronary artery disease, and procedures
related with any of the previous conditions. Afterwards, one
control subject without cardiac comorbidities or cardiovascular
risk factors (control group) and one subject who developed
cardiovascular risk factors (hypertension, hyperlipidemia, or/and
diabetes) at any point after the baseline session (cardiovascular
risk group) were matched to each subject in the cardiovascular
event group, so that a final subset of 99 subjects was obtained.
Matches were based on age (56.9 ± 4.4 years), gender (63
males, 36 females), BMI (28.1 ± 4.4 kg/m2), smoking habits (57
smokers at the time of the baseline session), and AHI (13.4 ±
TABLE 2 | Anthropometric data of the SHHS dataset.
Control Cardiovascular
risk
Cardiovascular
event
Total
Number of patients 33 33 33 99
Age (years) 55.8 ± 4.35 57.2 ± 4.2 57.8 ± 4.6 56.9 ± 4.4
Gender (male/female) 21 / 12 21 / 12 21 / 12 63 / 36
BMI (kg/m2) 28.3 ± 5.0 28.1 ± 4.5 27.9 ± 3.8 28.1 ± 4.4
AHI 13.8 ± 11.3 13.1 ± 10.1 13.3 ± 11.4 13.4 ± 10.9
Active smokers 19 19 19 57
BMI, Body Mass Index; AHI, Apnea Hypopnea Index; ACE, Angiotesin Converting
Enzyme.
10.9). The average recording duration was 08:27:38 (hh:mm:ss).
Demographics of each group are summarized in Table 2. Since
some subjects presented a lowAHI, only those with AHI≥ 5 were
considered in the further analysis (AHI = 5 remains the lower
limit for the diagnosis of moderate SAS). None of the subjects in
the two datasets suffered from atrial fibrillation.
As in the UZ Leuven database, PSGs were annotated by
sleep experts, and sleep stage classification (REM and NREM)
was available for each 30-s interval, together with the time of
occurrence and duration of each apneic/hypopneic episodes and
arousal. Since SHHS has several AHI measurements available,
we selected the one that best resembled the AASM 2012 scoring
(containing hypopneas with arousal/desaturation >3%). Bipolar
ECG (modified lead II) and thoracic respiratory effort (recorded
through respiratory inductive plethysmography) were acquired
at 125 and 10 Hz, respectively.
2.3. Preprocessing
Same preprocessing was applied to the databases described above.
First, bipolar ECG signals were resampled at 1,000 Hz with cubic
splines so that HRV analysis was not compromised by the effect
of the sampling frequency (Merri et al., 1990). Baseline wander
removal was accomplished by extracting the baseline with a low-
pass filter (0.5 Hz cut-off frequency). Afterwards, the baseline was
subtracted from the ECG signal.
Subsequently, QRS-complexes were detected by the wavelet-
based method proposed by Martínez et al. (2004). Ectopic
beat detection and correction was performed with the method
described by Mateo and Laguna (2003). Essentially, it consists
of thresholding instantaneous heart rate variations, so that
abnormal variations are detected and labeled as ectopics. Then,
ectopic beat positions and misdetections were corrected by using
the heart timing signal (Mateo and Laguna, 2003).
On the other hand, respiratory effort signals were resampled
at 4 Hz and respiratory rate, Fr, was estimated from them using
the method proposed by Bailón et al. (2006).
2.4. HRV Analysis
HRV has been largely supported as a tool for ANS assessment.
In this work, the HRV representation based on the time-varying
pulse integral frequency modulation (TVIPFM) model (Bailón
et al., 2011) was used. Given a beat time occurrence time series
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t = [t1 t2 . . . tk . . . tK], where k represents the k-th beat and
K is the total number of beats, the TVIPFM model allows to
generalize the series as:
k ≈
∫ tk
0
1+m(t)
T(t)
dt, (1)
where the instantaneous HR is represented by the term:
dHR(t) =
1+m(t)
T(t)
. (2)
Equation (2) is composed by two terms: the HRV signal,
m(t)/T(t), and the time-varying mean HR, 1/T(t). Under the
assumption that mean HR variations are slower than HRV, the
latter term can be easily obtained by low-pass filtering (0.03
Hz cut-off frequency) dHR(t). Defining the resulting signal as
dHRM(t) = 1/T(t), the continuous time version of the modulating
signal,m(t), which contains information of ANSmodulation, can
be obtained as:
m(t) =
dHR(t)− dHRM(t)
dHRM(t)
. (3)
Finally,m(n) was obtained by resamplingm(t) at 4 Hz.
Each 60 s HRV power spectral density, SˆHRV(j, F), was
estimated from the j-th segment of length 5 min of m(n) by the
Welch’s periodogram. Fifty-second Hamming windows with 50%
overlap were employed. Subsequently, the spectral indexes were
computed from SˆHRV(j, F).
Low-frequency (LF) power, PLF, was defined as the power in
the classical LF band ([0.04, 0.15] Hz) (Task Force, 1996). A
preliminary analysis of the respiratory rate revealed some values
close to 0.4 Hz, which remains the upper limit of the classical
high-frequency (HF) band ([0.15, 0.4] Hz) and could lead to an
underestimation of the HF power (PHF) (Bailón et al., 2007). For
this reason, two different alternative definitions of the HF band
were used:
cHF(j) = [max(0.15, Fr(j)− 0.125), Fr(j)+ 0.125]Hz
eHF(j) = [0.15, HR(j)/2]Hz, (4)
where cHF and 
e
HF stand for centered in Fr and extended HF
band respectively, and Fr(j) and HR(j) account for the mean
respiratory rate and HR in the j-th 5-min window. PcHF and P
e
HF
were defined as the power within cHF and 
e
HF, respectively. In
addition, LF to HF ratio, RLF/HF = PLF/PHF, and normalized LF
power, PLFn = PLF/(PLF+PHF) were also redefined to account for
the different versions of the HF band, so that RcLF/HF and P
c
LFn refer
tocHF whereas R
e
LF/HF and P
e
LFn are associated with
e
HF.
Also very low-frequency (VLF) power (PVLF) was considered,
being it defined as the power of dHRM, in order to account for
the slower variations of m(n). Finally, mean normal-to-normal
interval (NN) was defined as the mean RR interval within each
5-min window (Task Force, 1996).
2.5. Effect of Sleep Stages on HRV
Sleep stages are known to exert an important effect on HRV,
which is mainly reflected as an increased parasympathetic activity
during NREM sleep and an awake-like sympathetic activity
during REM sleep (Somers et al., 1993; Bušek et al., 2005). These
large inter-stage fluctuations make it advisable to consider sleep
stages in the analysis. In this way, HRV analysis was performed
for NREM and REM sleep separately, by considering PSG-based
sleep stage scoring.
2.6. Effect of Apneas, Hypopneas, and
Arousals on HRV
The complex physiological response to an apnea or hypopnea
usually finishes with an increase in sympathetic activity that may
trigger an arousal, thus biasing any possible measurement in that
period toward high sympathetic activity. Despite this well-known
effect, apneic episodes are usually included in the analysis. A
major innovation of this work is that the episodes of apneas,
hypopneas, and arousals (for simplicity summarized as apneic
episodes hereon) were removed from the analysis, so that ANS
activity can be assessed in a more basal state.
In order to minimize the effects of the recovery after an apneic
episode, the 1 min after the offset of each event was also removed,
since the tachycardia following an apnea or arousal often lasts
about 20–30 s (Stein and Pu, 2012). Some subjects presented
an extremely high number of events, and hence only a few 5-
min apneic episodes-free segments were usable (especially during
REM sleep, which is a shorter stage and with higher incidence of
apneic episodes). Thus, and to guarantee a minimum sample size,
subjects with less than 10 five-minute segments were discarded.
Nevertheless, the analysis was repeated including the apneic
episodes, so that the results were comparable with previous
studies. A schematic of the different proposed analyses is depicted
in Figure 1.
2.7. Effect of Medication
Patients in the cardiac comorbidity group of the UZ Leuven
dataset suffering from hypertension (33 out of 50) were under
anti-hypertensive medication at the time of the study. Each
patient was administered a different drug or combination
of drugs such as β-blockers, calcium channels inhibitors
or blockers, angiotensin converting enzyme inhibitors, and
diuretics, which are summarized in Table 1. Since anti-
hypertensives could directly alter HRV measurements (Guzzetti
et al., 1988; Bekheit et al., 1990), we considered medication intake
as a possible confounder in the analysis.
The effect of medication was analyzed in the following
manner. First, patients with cardiac comorbidities were divided
in two subgroups: under and not under anti-hypertensive
drugs intake. Afterwards, the differences of the mean NN and
PeLFn between each subject and his/her matched control were
computed, and the distributions obtained for the two subgroups
were compared.
2.8. Statistical Methods
The mean value of each parameter for the different sleep
stages was obtained for each subject. Normality of the data
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FIGURE 1 | A flowchart of the data analysis performed for each subject is displayed. First, the modulating signal was divided in periods corresponding to NREM
(black) and REM (gray) sleep. Afterwards, two different HRV analyses were performed in each of the sleep stages: one including the apneic episodes (red) and one
excluding them (the 1-min period after the apneic episodes are included in the segments highlighted in red). The HRV analyses are performed over 5-min windows of
available signal.
was rejected using a Kolmogorov-Smirnov test (p < 0.05) and
so a paired Wilcoxon signed-rank test was applied in order
to assess differences between the matched groups. This test
was applied twice: once considering apneas, hypopneas, and
arousals, and another time excluding them from the analysis.
When the comparison was between not matched groups, a two-
sided Wilcoxon rank-sum test was applied instead. Significance
level for considering statistical differences between groups was
set to 0.05.
3. RESULTS
In both datasets, results of the HRV analysis were similar when
defining the HF band aseHF or
c
HF so, for simplicity, only those
concerning the former are presented. The results obtained for
each of the two datasets are summarized below.
3.1. UZ Leuven Dataset
The results of the HRV analysis including and excluding
apneic episodes are presented in Table 3. A tendency toward
lower values of ReLF/HF and P
e
LFn in the cardiac comorbidity
group than in the control group was assessed when excluding
apneic episodes from the analysis. These differences were
statistically significant during NREM sleep. An example of
the mean overnight spectra of a control subject and his/her
comorbidity match during NREM sleep is displayed in Figure 2.
Similar results were obtained when including apneic episodes,
although significant differences were only assessed during
Frontiers in Physiology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 620
Milagro et al. ANS, Apnea, and Cardiac Risk
REM sleep in this case. Regarding the differences between
sleep stages, decreased NN and PeHF and increased R
e
LF/HF
and PeLFn were assessed during REM sleep. When excluding
apneic episodes from the analysis, also Fr was increased during
REM sleep.
The results obtained for the subgroups under and not under
medication intake are displayed in Figure 3. Whereas a higher
NN was assessed in the subgroup with medication, no differences
were found regarding PeLFn (although in Figure 3 only the
analysis during NREM sleep and excluding apneic episodes is
represented, no differences in PeLFn were found for REM sleep nor
when including apneic episodes).
3.2. SHHS Dataset
The results of the HRV analysis are summarized in Table 4. An
increased PeHF and decreased R
e
LF/HF and P
e
LFn were observed in
the cardiovascular risk and cardiovascular event groups when
compared to controls when excluding the apneic episodes.
In the cardiovascular event group, those differences turned
statistically significant for PeLFn during NREM sleep. Similar
results were obtained when including apneic episodes in the
analysis. In general, differences between sleep stages were noticed
as decreased NN and PeHF and increased R
e
LF/HF and P
e
LFn during
REM sleep. However, higher NN and lower PVLF were assessed
during REM than during NREM sleep in some cases (Tables 3,
4), but this is most likely due to the reduced number of segments
at REM sleep available for the analysis.
4. DISCUSSION
The main purpose of the present study was to assess whether
imbalanced autonomic activity could be related to CVD in
patients with SAS, as well as to investigate the potential use of
ANS activity analysis in the early stage identification of patients at
higher cardiovascular risk. ANS evaluation was achieved by HRV
analysis, since it has been largely supported as a non-invasive
tool for ANS activity assessment (Task Force, 1996). However,
HRV should be addressed carefully in nocturnal recordings, since
several studies have reported differences in HRV among the
different sleep stages (Somers et al., 1993; Bušek et al., 2005).
Also differences in HRV when comparing subjects with and
without apneas have been described in the literature (Gula et al.,
2003; Penzel et al., 2003). Nevertheless, whereas the effect of
sleep stages is often considered in overnight HRV analysis, the
effect of apneic episodes has been largely ignored. In this way,
increased sympathetic dominance assessed in SAS patients might
be reflecting the adrenergic surge following apneas and not a
chronic sympathetic nervous system (SNS) dominance during
rest. For this reason, in this work we proposed to discard apneic
episodes from the analysis, so that ANS evaluation is performed
during the most basal condition.
The effect of excluding apneic episodes from the analysis can
be noticed in both datasets (Tables 3, 4), with large significant
differences in PLF and sympathovagal balancemeasurements. The
apparent reduction observed in sympathetic activity when not
considering the periods of apnea suggests that apneic episodes
do alter ANS assessment by HRV and hence should be removed
from the analysis, since changes in sympathetic activity unrelated
to apneas might be masked otherwise. Moreover, this effect was
more evident for the patients in the UZ Leuven dataset, with
larger AHI than in the SHHS.
With respect to the different definitions of the HF band
employed in HRV analysis, eHF resulted to be the most
discriminative between groups, specially when apneic episodes
were excluded from the analysis (although similar results were
achieved withcHF). The motivation for considering modified HF
bands was that a preliminary analysis of Fr revealed the existence
of some high values, which could yield to a power shift outside
the band and hence result in underestimations of the real power.
In this way, one possible solution is to center the band into the
estimated respiratory rate, so that respiratory-related power lays
inside the band. Besides, the fact that better results were obtained
when considering eHF could be related with differences in HR
(as the higher limit of the extended band was selected as HR/2
Hz, since HR remains the intrinsic sampling rate of HRV; Laguna
et al., 1998), although the absence of significant differences in the
NN of the distinct groups in both datasets suggests that this is
not a likely explanation for the obtained results. Alternatively, the
non-linear interaction between HR and respiration during sleep
(Varon and Van Huffel, 2017) may result in important frequency
components that lie outside the classic and the centered bands.
4.1. UZ Leuven Dataset
In order to study the relationship between ANS, SAS, and
CVD, we considered the UZ Leuven database described in
section 2.1, since it is composed by SAS patients with and
without cardiac comorbidities that were matched based on
age, gender, BMI, and smoking habits. When comparing
the patients with cardiac comorbidities with their matched
controls a decreased sympathovagal balance, as assessed by
lower values of ReLF/HF and P
e
LFn, was observed in the former
(Table 3). This decreased sympathetic dominance, exemplified in
Figure 2, could reflect a lack of adaptability of ANS and hence
incapability to restore homeostasis after an apneic episode. If
this was the case, an inefficient response to oxygen deprivation
could directly affect the cardiovascular system, leading to
inflammation (Somers et al., 2008), oxidative stress (Suzuki
et al., 2006), or tonic chemoreceptor activation (Narkiewicz
et al., 1998) among others, which are intrinsically related with
the development of CVDs (Somers et al., 2008). The fact that
statistically significant differences were observed in NREM when
excluding apneic episodes from the analysis but not when
including them might suggest that the sympathetic activations
following apneas could be masking the lowered sympathetic
dominance in the comorbidity group. On the other hand,
the increased incidence of apneic episodes during REM sleep
(Sackner et al., 1975) results in a reduction in the number
of subjects considered in the analysis when excluding them,
which could explain the absence of significant differences during
this sleep stage. Similarly to previous studies (Somers et al.,
1993; Bušek et al., 2005), a higher sympathetic tone was
assessed during REM than during NREM sleep, as reflected in
increased PLF, R
e
LF/HF, and P
e
LFn and decreased NN and P
e
HF in
the former.
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TABLE 3 | Results of HRV analysis for the UZ Leuven dataset.
Control Cardiac comorbidity
NREM REM NREM REM
EXCLUDING APNEIC EPISODES
Fr (Hz) 0.23 (0.06) 0.25 (0.06)
∗ 0.23 (0.07) 0.25 (0.08)∗
NN (ms) 920.13 (184.89) 939.09 (178.61)∗ 951.08 (173.29) 911.34 (177.57)∗
PVLF (a.u.) 1.16 (0.40) 1.12 (0.40)
∗ 1.09 (0.42) 1.20 (0.41)∗
PLF (a.u.) 0.0005 (0.0006) 0.0006 (0.0015) 0.0005 (0.0007) 0.0008 (0.0013)
PeHF (a.u.) 0.0005 (0.0010) 0.0003 (0.0005)
∗ 0.0006 (0.0016) 0.0005 (0.0012)∗
Re
LF/HF
(n.u.) 0.96 (1.12) 2.43 (3.14)∗ 0.69 (0.94)† 1.52 (1.77)∗
PeLFn (n.u.) 0.47 (0.24) 0.68 (0.22)
∗ 0.38 (0.23)† 0.60 (0.19)∗
N (subjects) 43 29 42 25
INCLUDING APNEIC EPISODES
Fr (Hz) 0.23 (0.05) 0.23 (0.07) 0.23 (0.06) 0.24 (0.07)
NN (ms) 938.53 (200.44) 936.66 (198.97)∗ 950.39 (155.86) 900.00 (125.60)∗
PVLF (a.u.) 1.13 (0.42) 1.12 (0.48)
∗ 1.10 (0.37) 1.23 (0.32))∗
PLF (a.u.) 0.0011 (0.0013) 0.0012 (0.0020) 0.0010 (0.0015) 0.0009 (0.0014)
†
PeHF (a.u.) 0.0006 (0.0012) 0.0004 (0.0006)
∗ 0.0008 (0.0016) 0.0005 (0.0009)∗
Re
LF/HF
(n.u.) 1.79 (2.56) 3.16 (3.41)∗ 1.42 (1.50) 1.72 (2.32)†,∗
PeLFn (n.u.) 0.59 (0.28) 0.72 (0.20)
∗ 0.52 (0.21) 0.60 (0.22)†,∗
N (subjects) 46 50 49 46
Results are displayed as median (interquartile range), except for the number of subjects. Significant differences with the same sleep stage of the control group are marked with † (p <
0.05). Significant differences between NREM and REM sleep within each group are marked with * (p < 0.05).
FIGURE 2 | Average spectra for all the NREM segments (excluding those with apneic episodes) of a control subject of the UZ Leuven dataset (black) and his match
(gray) are displayed. An increased sympathetic dominance can be noticed in the control subject, as reflected by the relative higher low frequency power content. The
dashed black lines indicate the boundaries of the low frequency band. The number of averaged 5 min segments was 50 and 36 for the control and the match,
respectively. As estimated from the modulating signal, the power spectral density is given in arbitrary units (a.u.).
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FIGURE 3 | Boxplots of the differences in mean NN (1NN) and PeLFn (1P
e
LFn) between the control subjects of the UZ Leuven dataset and their matches under or not
under medication intake (during NREM sleep and excluding apneic episodes). Whereas, 1NN is increased in the group under medication intake when compared to
the group without medication (p < 0.05, indicated with *), no differences in 1PeLFn were assessed.
TABLE 4 | Results of HRV analysis for the SHHS dataset.
Control Cardiovascular risk Cardiovascular event
NREM REM NREM REM NREM REM
EXCLUDING APNEIC EPISODES
Fr (Hz) 0.25 (0.05) 0.24 (0.03) 0.24 (0.04) 0.25 (0.03) 0.25 (0.05) 0.24 (0.07)
NN (ms) 925.95 (150.24) 924.58 (123.65) 980.00 (168.87) 959.41 (266.71) 914.59 (201.34) 919.62 (186.39)∗
PVLF (a.u.) 1.16 (0.35) 1.15 (0.33) 1.03 (0.34) 1.07 (0.60) 1.18 (0.47) 1.17 (0.51)
∗
PLF (a.u.) 0.0004 (0.0004) 0.0005 (0.0009) 0.0004 (0.0005) 0.0004 (0.0026) 0.0003 (0.0002) 0.0003 (0.0003)
PeHF (a.u.) 0.0002 (0.0003) 0.0001 (0.0002) 0.0004 (0.0005) 0.0006 (0.0007) 0.0003 (0.0005) 0.0001 (0.0001)
∗
Re
LF/HF
(n.u.) 1.13 (1.01) 3.99 (2.62)∗ 0.94 (1.21) 2.01 (2.38) 0.97 (0.99) 1.65 (4.06)
PeLFn (n.u.) 0.49 (0.17) 0.79 (0.11)
∗ 0.45 (0.28) 0.67 (0.30)∗ 0.43 (0.28)† 0.59 (0.36)
N (subjects) 23 6 24 7 22 6
INCLUDING APNEIC EPISODES
Fr (Hz) 0.26 (0.05) 0.25 (0.04) 0.24 (0.04) 0.26 (0.04) 0.25 (0.05) 0.25 (0.04)
NN (ms) 922.36 (158.63) 929.32 (154.77) 992.65 (144.38) 1016.15 (134.91)∗ 929.90 (217.02) 897.97 (154.08)
PVLF (a.u.) 1.16 (0.39) 1.15 (0.36) 1.01 (0.30) 0.96 (0.26)
∗ 1.16 (0.52) 1.22 (0.42)
PLF (a.u.) 0.0005 (0.0006) 0.0005 (0.0006) 0.0006 (0.0008) 0.0007 (0.001) 0.0004 (0.0005) 0.0005 (0.0007)
PeHF (a.u.) 0.0002 (0.0003) 0.0002 (0.0001)
∗ 0.0005 (0.0005) 0.0004 (0.0004)† 0.0004 (0.0005) 0.0002 (0.0001)∗
Re
LF/HF
(n.u.) 1.74 (1.08) 3.19 (2.94)∗ 1.39 (1.26) 2.09 (2.22)∗ 1.09 (1.27)† 2.86 (2.25)∗
PeLFn (n.u.) 0.55 (0.13) 0.74 (0.18)
∗ 0.53 (0.24) 0.66 (0.22)∗ 0.46 (0.24)† 0.67 (0.26)∗
N (subjects) 25 23 26 25 25 22
Results are displayed as median (interquartile range), except for the number of subjects. Significant differences with the same sleep stage of the control group are marked with † (p <
0.05). Significant differences between NREM and REM sleep within each group are marked with * (p < 0.05).
Nevertheless, altered sympathovagal balance should be
regarded carefully, as 33 out of 50 patients in the cardiac
comorbidity group were under anti-hypertensive medication
at the time of the recordings. Since anti-hypertensives could
contribute to reduced cardiac sympathetic activity (Guzzetti
et al., 1988; Bekheit et al., 1990), a more detailed analysis
was performed in order to check whether the observed
differences could be explained by medication intake. In this
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way, the differences in mean NN and PeLFn of the patients
under medication and their matched controls were compared
to those of the patients without medication (Figure 3). The
results revealed a higher NN, i.e., a lower HR, in those
patients under anti-hypertensives, as expected, although no
differences were found in PeLFn. The lowered NN in the
medication group would be reflected as an increase in the
mean HR which is corrected in the TVIPFM model (see
Equation 3) and hence is not expected to have a big
influence in the analysis. On the other hand, PeLFn was
apparently independent of the use of medication, possibly due
to the mentioned correction by mean HR intrinsic to the
TVIPFMmodel.
4.2. SHHS Dataset
Moreover, in order to evaluate if altered ANS activity may
be prior to cardiovascular disorders in subjects with SAS, a
second dataset consisting of a subset of the SHHS and described
in section 2.2 was considered. Again, HRV analysis revealed
a decreased sympathetic dominance in the cardiovascular
risk and cardiovascular event groups (Table 4), which turned
statistically significant in the case of the cardiovascular event
group (during NREM sleep). Given that subjects in the
cardiovascular event group presented an altered sympathovagal
balance when compared with their matched controls, despite
the fact that they did not suffer from any CVD at the
time of the recording, it is possible that individuals with
SAS and altered sympathovagal balance are at augmented
risk for developing CVDs. This unbalanced sympathovagal
activity may be an indicator of either a lowered SNS
activity, a dysfunction in the response to SNS stimuli or a
combination of both. Although decreased LF variability has
been assessed in severe chronic heart failure (Van De Borne
et al., 1997), this effect appears to be visible only in
the most advanced stages of the disease. Nonetheless, the
desensitization of β-adrenergic receptors when subjected to
a recurrent stimuli (Barnes, 1995) could point to SAS as
a possible precursor of CVD, as heart damage has been
associated with decreased β-adrenergic receptors density and
decreased sensitivity to adrenergic stimulation (Bristow et al.,
1982). Regarding the differences between sleep stages, increased
sympathetic dominance was generally observed during REM
sleep as expected.
4.3. Limitations
There are some limitations in this study that must be
mentioned. The first and most important one is the use of anti-
hypertensive medication by a large subset of subjects in the UZ
Leuven database, which might compromise the physiological
interpretation. Although differences that may be induced by
medication intake were analyzed carefully, it is not possible to
ensure that it does not have an effect on the results. Moreover,
there is controversy in the literature, with some studies reporting
absence of changes in the sympathovagal balance in subjects
under β-blockers (Goldsmith et al., 1997; Malfatto et al., 1998),
and some others suggesting altered sympathetic dominance
(Sandrone et al., 1994; Lin et al., 1999). Another limitation is that
the proposed analysis for ANS assessment is only valid during
sinus rhythm and it is not applicable to other scenarios. This
limitation takes special relevance in the case of atrial fibrillation,
since it is known to be associated with SAS (Tietjens et al.,
2019). Regarding sleep stages, no distinction was made between
light and deep NREM sleep due to the extremely low number
of deep sleep epochs (less than 5% of the recording duration
in most of the subjects in the UZ Leuven dataset, prior to
apneic epochs deletion). In the SHHS dataset, the low number
of analyzed subjects during REM sleep after removing apneic
episodes compromises the further physiological interpretation.
On the other hand, whereas the results obtained for both datasets
are coherent, the datasets are not comparable, due to differences
in mean age and AHI, and to the fact that cardiac comorbidity
subjects in the UZ Leuven dataset had already developed CVDs.
It is also important to highlight that subjects in UZ Leuven
attended to the sleep laboratory because of complains and/or
symptoms related to SAS, whereas volunteers in SHHS did not
report any interference with their daily life, regardless of their
scored AHI. Finally, and although several cardiac conditions with
different origin and effects were considered simultaneously, the
scope of this work was limited to the risk of developing CVDs
as a whole.
5. CONCLUSION
The combination of all the underlying mechanisms that act
in response to an apneic episode, together with the functional
alterations caused by the different CVD, result in a very
complex frame that obscures the physiological interpretation.
Despite, decreased sympathetic dominance was assessed in SAS
patients suffering from cardiac comorbidities. Furthermore,
retrospective analysis of the subjects with SAS that will develop
cardiovascular events in the future also revealed a reduced
sympathetic dominance. Notwithstanding that further work
is needed in the field of SAS phenotyping, HRV analysis
could represent a useful tool for improving the screening
and diagnosis of SAS patients with increased cardiovascular
risk. Moreover, the importance of considering the effect of
the apneic episodes in the interpretation of HRV analysis
was addressed.
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